U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...

Bicara Therapeutics is well-capitalized, with over $414.8M in cash and funding runway into H1 2029, but faces competitive ...

A proprietary monoclonal antibody targeting an inhibitory immune checkpoint pathway had favorable safety and tolerability in ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

A vaccine that is injected directly into tumours could boost survival rates from hard-to-treat cancers.

Researchers have found that amlodipine, a calcium-channel blocker prescribed to tens of millions of people for high blood ...

Agilent has received FDA approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with esophageal or gastroesophageal junction carcinoma eligible for ...

Agenus begins patient enrolment in global phase 3 BATTMAN trial of BOT+BAL immunotherapy combination in MSS/pMMR metastatic colorectal cancer: Lexington, Massachusetts Thursday, A ...

Researchers from Peking University discovered a tumor-specific biomarker that can predict which gastric cancer patients will ...